Comment on ‘The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-α inhibitor: a systematic review and meta-analysis’: risk of cancer recurrence with biologics in psoriasis
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf031 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Aparna Potluru und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Leicester Royal Infirmary, NHS East Midlands, UK. Hauptthemen laut MEDLINE: Biological Products, Neoplasms, Psoriasis, Skin Neoplasms. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Teaser Text This article reviews the findings of Wu et al. regarding the risk of malignancy in patients with psoriasis who were treated with long-term tumour necrosis factor-α inhibitors. While the study found no significant increase in the risk of most cancers, it highlighted a higher risk of nonmelanoma skin cancers, particularly squamous cell carcinoma, in patients with psoriatic arthritis. The article discusses the clinical implications for patients with psoriasis who have a history of malignancy, advocating for a personalized treatment approach, vigilant monitoring and the need for further research to better understand the relationship between biologic therapy and cancer recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Leicester Royal Infirmary, NHS East Midlands, UK.
- Guy's and St Thomas' Hospital NHS Trust, UK.
ORCID-Profile: Aparna Potluru, Yasmin Nikookam
Zitieren
APA
Potluru, A., & Nikookam, Y. (2025). Comment on ‘The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-α inhibitor: a systematic review and meta-analysis’: risk of cancer recurrence with biologics in psoriasis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf031
Vancouver
Potluru A, Nikookam Y. Comment on ‘The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-α inhibitor: a systematic review and meta-analysis’: risk of cancer recurrence with biologics in psoriasis. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf031
BibTeX
@article{Potluru2025,
author = {Potluru, Aparna and Nikookam, Yasmin},
title = {Comment on ‘The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-α inhibitor: a systematic review and meta-analysis’: risk of cancer recurrence with biologics in psoriasis},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf031}
}
EUVIMED